大華繼顯:重申石藥集團(1093.HK)買入評級 目標價上調至12.3港元
石藥集團(1093.HK)公佈去年全年業績,大華繼顯發表研究報吿指,公司去年全年收入及純利分別增上12.8%及38.9%,而核心盈利按年升18%,表現符合預期,認為公司具有強勁的產品管線,短期內亦有數只具有潛力的藥品正處於審評待批階段,公司前景明朗,將目標價由10.76港元上調至12.3港元,重申買入評級。
該行指,公司創新藥產品恩必普價格受壓已反映於現時股價,預期恩必普未來銷售增長將會走強,未來具有潛力但正處於審評待批階段的藥品將於2022年成為增長動力,公司去年在研發方面投入28.9億元人民幣,按年增加約44.5%,認為多元化的創新管線將會帶動公司長期盈利增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.